Skip to main content
logo
ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,010.00
-100.00 (-4.74%)
At close: Aug 11, 2026

ADBiotech Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
12,51312,89711,13610,47210,63211,840
Revenue Growth
1.74%15.81%6.34%-1.50%-10.21%20.63%
Gross Profit
4,8425,1484,0073,2183,1115,009
Operating Income
-4,362-3,501-4,117-4,772-4,984-1,555
Net Income
-8,331-3,304-7,952-2,8632,696-2,664
Earnings Per Share
-578.99-275.09-870.00-313.27118.54-347.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
5,57411,4701,6799,4148,6282,781
Total Debt
13,39916,80211,97213,61012,77113,168
Net Cash (Debt)
-7,825-5,332-10,292-4,196-4,143-10,388
Net Cash Growth
------
Net Cash Per Share
-543.85-443.97-1126.04-459.08-410.96-1351.57

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
766.49-1,319-4,092314.93-8,592-2,186
Capital Expenditures
-15,844-15,811-193.38-239.9-726.72-3,561
Free Cash Flow
-15,078-17,130-4,28575.03-9,319-5,747
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
38.69%39.91%35.98%30.73%29.26%42.31%
Operating Margin
-34.86%-27.15%-36.97%-45.57%-46.88%-13.13%
Pretax Margin
-66.36%-27.20%-80.93%-52.11%25.36%-20.39%
Profit Margin
-66.58%-25.62%-71.41%-27.34%25.36%-22.50%
FCF Margin
-120.50%-132.82%-38.48%0.72%-87.66%-48.54%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----11.39-
P/FCF Ratio
---398.99--
PS Ratio
4.332.581.712.862.893.81